In vitro, GHRH stimulated multiple pathways involved in inflammation and growth in both benign prostatic hyperplasia‐1 and PrEp cells including NFκB p65, AKT, ERK1/2, EGFR, STAT3 and increased the levels of TGF‐β1 and snail/slug. GHRH also stimulated the transactivation of the IGF receptor. [Prostate]
Abstract

As prostate‐specific membrane antigen is highly overexpressed on malignant prostate tumor cells and as its expression rate correlates with the aggressiveness of the disease, this tumor‐associated biomarker provides the possibility to develop new strategies for diagnostics and therapy of prostate cancer. [Med Res Rev]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

Twenty five years after it opened for enrollment, the landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens’ risk of getting prostate cancer without increasing their risk of dying from the disease. [Press release from SWOG discussing research presented at the 2018 American Urological Association (AUA) Annual Meeting, San Francisco]
Press Release

Sun Pharmaceutical Industries Ltd. and Churchill Pharmaceuticals, LLC. announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the FDA for YONSA®, a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer. [Sun Pharmaceutical Industries Ltd. (Business Wire Inc.)]
Press Release

SOTIO announced that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming engineered human serotype 5 adenovirus, for patients with prostate cancer. [SOTIO]
Press Release

The electoral victory of two populist parties in March had Italian scientists worried that a new era of antiscientific policies might be around the corner—and appointment of Giuseppe Conte as the country’s new prime minister is making some even more nervous. [ScienceInsider]
Editorial

A professor who received about $5 million in grants from the National Institutes of Health left his posts at the University of Alabama, Birmingham, and Birmingham VA Medical Center last year after an investigation found evidence of image manipulation in 20 of his papers, Retraction Watch has learned. [The Scientist]
Editorial

The Prime Minister made the strongest commitment yet to “fully associate” the UK with the EU’s £68bn research program post-Brexit. Theresa May said the UK would be willing to make “an appropriate contribution” and in return it would expect a “suitable level of influence”. [BBC News]
Editorial